查看購物車
  • Simplified Chinese
  • English
2021-2031年歐洲抗生素和抗真菌藥物市場報告：範圍、細分、動態和競爭分析
市場調查報告書
商品編碼
1871448

2021-2031年歐洲抗生素和抗真菌藥物市場報告：範圍、細分、動態和競爭分析

Europe Antibiotics & Antimycotics Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 197 Pages | 訂單完成後即時交付

價格

歐洲抗生素和抗真菌藥物市場預計將大幅成長，到 2031 年將達到約 198.7 億美元，高於 2023 年的 134.8 億美元，預測期內年複合成長率(CAGR) 為 5.0%。

執行摘要和市場分析

市場分為多個區域，包括英國、德國、法國、義大利、西班牙和歐洲其他地區。市場成長的主要驅動力是細菌和真菌感染發生率的上升，以及各國政府為促進合理使用抗生素和抗真菌藥物而採取的措施。此外，產品發布、法規核准和主要產業參與者之間的合作等策略措施預計也將進一步刺激歐洲市場成長。

市場區隔

歐洲抗生素和抗真菌藥物市場分析按藥物類別、適應症、給藥途徑和配銷通路進行分類：

  • 藥物類別：市場涵蓋多種藥物類別，例如青黴素類、頭孢菌素類、碳青黴烯類、大環內酯類、氨基糖苷類、喹諾酮類、磺胺類、四環素類、唑類等。 2023年，青黴素類佔據最大的市佔率。
  • 適應症：市場細分為皮膚感染、呼吸道感染、泌尿道感染、敗血症、耳部感染、胃腸道感染及其他感染。 2023年，呼吸道感染佔最大市場佔有率。
  • 給藥途徑：包括口服、外用及其他方法，其中口服給藥在 2023 年最為常見。
  • 配銷通路：市場分為醫院藥房、零售藥房和線上藥房，其中醫院藥房在 2023 年的市場佔有率領先。

市場展望

抗生素和抗真菌藥物行業的公司正積極致力於開發新產品和改進現有產品，並獲得了藥物研發和臨床試驗的資金支持。近期市場發展動態包括：

  • 2024 年 9 月，總部位於英國的生物製藥公司 F2G 獲得了 1 億美元的資金，用於推進 olorofim 的後期開發。 olorofim 是一種新型口服抗真菌藥物，用於治療侵襲性麴菌病和其他真菌感染。
  • 2024 年 6 月，全球抗生素研發合作組織 (GARDP) 與 Bugworks Research Inc. 合作開發了 BWC0977，這是一種針對多重抗藥性細菌的廣譜抗生素。
  • 2023 年 6 月，BioVersys 成為第一家獲得 AMR 行動基金資助的歐洲公司，用於開展旨在對抗細菌抗藥性的臨床試驗，並計劃在 2030 年前推出 2-4 種新的抗菌藥物。
  • 2022 年 10 月，CARB-X 啟動了幾輪以關鍵健康需求為重點的融資，包括治療新生兒敗血症和淋病的療法，以解決緊迫的抗菌素抗藥性問題。

這些持續的資金投入和研究計畫有望在未來幾年為抗生素和抗真菌藥物市場創造巨大的成長機會。

國家概況

按國家/地區分類的市場分析顯示，德國在2023年佔據最大市場佔有率。德國的成長歸因於細菌和真菌感染的高發生率以及人們對抗菌素抗藥性（AMR）認知的提高。報告顯示，德國每年有超過50萬人罹患肺炎，其中相當一部分人需要住院治療。此外，羅伯特·科赫研究所報告稱，每年有40萬至60萬名患者發生醫院感染，造成數千人死亡。

德國政府已實施多項措施以促進抗生素的永續使用，其中包括旨在最佳化處方行為的《德國抗生素抗藥性策略》（DART 2030）。市場參與者之間的合作，例如勃林格殷格翰、Evotec 和 bioMerieux 於 2022 年 6 月成立的合資企業 Aurobac，預計也將促進市場成長。

公司簡介

抗生素和抗真菌藥物市場的主要參與者包括輝瑞公司、諾華公司、賽諾菲公司、羅氏公司、默克公司、葛蘭素史克公司、強生公司、西普拉公司、拜耳公司、艾伯維公司和安斯泰來製藥公司。這些公司正在推行各種策略，包括擴張、產品創新以及併購，以增強其市場佔有率並為消費者提供創新解決方案。

目錄

第1章：引言

第2章：執行概要

  • 關鍵見解

第3章：研究方法

  • 二手研究
  • 初步研究
    • 假設的提出：
    • 宏觀經濟因素分析：
    • 發展基礎數字：
    • 數據三角測量：
    • 國家層面資料：

第4章：歐洲抗生素和抗真菌藥物市場－主要市場動態

  • 市場促進因素
    • 傳染病發生率不斷上升
    • 人們對真菌感染的認知不斷提高
  • 市場限制
    • 抗菌素抗藥性、經濟障礙和繁瑣的監管程序
  • 市場機遇
    • 持續的資金投入與研發計劃
  • 未來趨勢
    • 產品開發和治療輸送方法的技術進步
  • 駕駛員和安全帶的影響：

第5章：抗生素和抗真菌藥物市場——歐洲分析

  • 2021-2031年歐洲抗生素和抗真菌藥物市場收入
  • 歐洲抗生素和抗真菌藥物市場預測分析

第6章：歐洲抗生素與抗黴菌藥物市場分析－依藥物類別分類

  • 青黴素
  • 頭孢菌素
  • 碳青黴烯類
  • 大環內酯類
  • 氨基糖苷類
  • 奎諾酮類
  • 磺胺類藥物
  • 四環素類
  • 唑類
  • 其他

第7章：歐洲抗生素與抗黴菌藥物市場分析－依適應症分類

  • 皮膚感染
  • 呼吸道感染
  • 泌尿道感染（UTI）
  • 敗血症
  • 耳部感染
  • 胃腸道感染
  • 其他

第8章：歐洲抗生素和抗真菌藥物市場分析－按給藥途徑分類

  • 口服
  • 主題
  • 其他

第9章：歐洲抗生素和抗真菌藥物市場分析－按配銷通路分類

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第10章：歐洲抗生素和抗真菌藥物市場——國別分析

  • 歐洲
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 英國
    • 歐洲其他地區

第11章：抗生素和抗真菌藥物市場——產業概況

  • 概述
  • 抗生素和抗真菌藥物市場成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第12章：公司簡介

  • Pfizer Inc
  • Novartis AG
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • GSK Plc
  • Johnson & Johnson
  • Cipla Ltd
  • Bayer AG
  • AbbVie Inc
  • Astellas Pharma Inc

第13章：附錄

Product Code: BMIRE00032105

The European antibiotics and antimycotics market is projected to grow significantly, reaching approximately USD 19.87 billion by 2031, up from USD 13.48 billion in 2023, reflecting a compound annual growth rate (CAGR) of 5.0% during the forecast period.

Executive Summary and Market Analysis

The market is divided into several regions, including the UK, Germany, France, Italy, Spain, and the Rest of Europe. The growth of this market is primarily driven by the rising incidence of bacterial and fungal infections, alongside increasing government initiatives aimed at promoting the responsible use of antibiotics and antimycotics. Additionally, strategic actions such as product launches, regulatory approvals, and collaborations among key industry players are expected to further stimulate market growth in Europe.

Market Segmentation

The analysis of the European antibiotics and antimycotics market is categorized based on drug class, indication, route of administration, and distribution channel:

  • Drug Class: The market includes various drug classes such as penicillins, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. In 2023, penicillins held the largest market share.
  • Indication: The market is segmented into skin infections, respiratory infections, urinary tract infections (UTIs), septicemia, ear infections, gastrointestinal infections, and others. Respiratory infections accounted for the largest share in 2023.
  • Route of Administration: This includes oral, topical, and other methods, with oral administration being the most prevalent in 2023.
  • Distribution Channel: The market is divided into hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies leading in market share in 2023.

Market Outlook

Companies in the antibiotics and antimycotics sector are actively engaged in developing new products and enhancing existing ones, supported by funding for drug development and clinical trials. Recent developments in the market include:

  • In September 2024, F2G, a UK-based biopharmaceutical firm, secured USD 100 million to advance the late-stage development of olorofim, a novel oral antifungal treatment for invasive aspergillosis and other fungal infections.
  • In June 2024, the Global Antibiotic Research & Development Partnership (GARDP) collaborated with Bugworks Research Inc. to develop BWC0977, a broad-spectrum antibiotic targeting multidrug-resistant bacteria.
  • In June 2023, BioVersys became the first European company to receive funding from the AMR Action Fund for clinical trials aimed at combating bacterial resistance, with plans to launch 2-4 new antimicrobials by 2030.
  • In October 2022, CARB-X initiated funding rounds focused on critical health needs, including therapeutics for neonatal sepsis and gonorrhea, addressing urgent antimicrobial resistance issues.

These ongoing funding and research initiatives are expected to create significant growth opportunities in the antibiotics and antimycotics market in the coming years.

Country Insights

The market analysis by country reveals that Germany held the largest share in 2023. The growth in Germany is attributed to the high prevalence of bacterial and fungal infections and increased awareness of antimicrobial resistance (AMR). Reports indicate that over 500,000 individuals in Germany are affected by pneumonia annually, with a substantial number requiring hospitalization. Furthermore, the Robert Koch Institute reported that 400,000 to 600,000 patients experience hospital-acquired infections each year, leading to thousands of deaths.

The German government has implemented various initiatives to promote sustainable antibiotic use, including the German Antibiotic Resistance Strategy (DART 2030), which focuses on optimizing prescribing practices. Collaborative efforts among market players, such as the joint venture Aurobac launched by Boehringer Ingelheim, Evotec, and bioMerieux in June 2022, are also expected to enhance market growth.

Company Profiles

Key players in the antibiotics and antimycotics market include Pfizer Inc., Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc., and Astellas Pharma Inc. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Europe Antibiotics and Antimycotics Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Increasing Prevalence of Infectious Diseases
    • 4.1.2 Growing Awareness About Fungal Infections
  • 4.2 Market Restraints
    • 4.2.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
  • 4.3 Market Opportunities
    • 4.3.1 Ongoing Funding and Research & Development Initiatives
  • 4.4 Future Trends
    • 4.4.1 Technological Advancements in Product Development and Treatment Delivery Approaches
  • 4.5 Impact of Drivers and Restraints:

5. Antibiotics and Antimycotics Market - Europe Analysis

  • 5.1 Europe Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • 5.2 Europe Antibiotics and Antimycotics Market Forecast Analysis

6. Europe Antibiotics and Antimycotics Market Analysis - by Drug Class

  • 6.1 Penicillin
    • 6.1.1 Overview
    • 6.1.2 Penicillin: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.2 Cephalosporines
    • 6.2.1 Overview
    • 6.2.2 Cephalosporines: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.3 Carbapenems
    • 6.3.1 Overview
    • 6.3.2 Carbapenems: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.4 Macrolides
    • 6.4.1 Overview
    • 6.4.2 Macrolides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.5 Aminoglycosides
    • 6.5.1 Overview
    • 6.5.2 Aminoglycosides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.6 Quinolones
    • 6.6.1 Overview
    • 6.6.2 Quinolones: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.7 Sulfonamides
    • 6.7.1 Overview
    • 6.7.2 Sulfonamides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.8 Tetracyclines
    • 6.8.1 Overview
    • 6.8.2 Tetracyclines: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.9 Azoles
    • 6.9.1 Overview
    • 6.9.2 Azoles: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.10 Others
    • 6.10.1 Overview
    • 6.10.2 Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Europe Antibiotics and Antimycotics Market Analysis - by Indication

  • 7.1 Skin Infections
    • 7.1.1 Overview
    • 7.1.2 Skin Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Respiratory Infections
    • 7.2.1 Overview
    • 7.2.2 Respiratory Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Urinary Tract Infections (UTI)
    • 7.3.1 Overview
    • 7.3.2 Urinary Tract Infections (UTI): Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Septicemia
    • 7.4.1 Overview
    • 7.4.2 Septicemia: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.5 Ear Infections
    • 7.5.1 Overview
    • 7.5.2 Ear Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.6 Gastrointestinal Infections
    • 7.6.1 Overview
    • 7.6.2 Gastrointestinal Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Antibiotics and Antimycotics Market Analysis - by Route Of Administration

  • 8.1 Oral
    • 8.1.1 Overview
    • 8.1.2 Oral: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Topical
    • 8.2.1 Overview
    • 8.2.2 Topical: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Antibiotics and Antimycotics Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 Retail Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.3 Online Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Online Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Antibiotics and Antimycotics Market - Country Analysis

  • 10.1 Europe
    • 10.1.1 Europe Antibiotics and Antimycotics Market Overview
    • 10.1.2 Europe Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 10.1.2.1 Europe Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 10.1.2.2 Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.2.2.1 Germany: Europe Antibiotics and Antimycotics Market Share - by Drug Class
        • 10.1.2.2.2 Germany: Europe Antibiotics and Antimycotics Market Share - by Indication
        • 10.1.2.2.3 Germany: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 10.1.2.2.4 Germany: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 10.1.2.3 France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.2.3.1 France: Europe Antibiotics and Antimycotics Market Share - by Drug Class
        • 10.1.2.3.2 France: Europe Antibiotics and Antimycotics Market Share - by Indication
        • 10.1.2.3.3 France: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 10.1.2.3.4 France: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 10.1.2.4 Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.2.4.1 Spain: Europe Antibiotics and Antimycotics Market Share - by Drug Class
        • 10.1.2.4.2 Spain: Europe Antibiotics and Antimycotics Market Share - by Indication
        • 10.1.2.4.3 Spain: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 10.1.2.4.4 Spain: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 10.1.2.5 Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.2.5.1 Italy: Europe Antibiotics and Antimycotics Market Share - by Drug Class
        • 10.1.2.5.2 Italy: Europe Antibiotics and Antimycotics Market Share - by Indication
        • 10.1.2.5.3 Italy: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 10.1.2.5.4 Italy: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 10.1.2.6 United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.2.6.1 United Kingdom: Europe Antibiotics and Antimycotics Market Share - by Drug Class
        • 10.1.2.6.2 United Kingdom: Europe Antibiotics and Antimycotics Market Share - by Indication
        • 10.1.2.6.3 United Kingdom: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 10.1.2.6.4 United Kingdom: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 10.1.2.7 Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.2.7.1 Rest of Europe: Europe Antibiotics and Antimycotics Market Share - by Drug Class
        • 10.1.2.7.2 Rest of Europe: Europe Antibiotics and Antimycotics Market Share - by Indication
        • 10.1.2.7.3 Rest of Europe: Europe Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 10.1.2.7.4 Rest of Europe: Europe Antibiotics and Antimycotics Market Share - by Distribution Channel

11. Antibiotics and Antimycotics Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Antibiotics and Antimycotics Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Pfizer Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Novartis AG
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Sanofi SA
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 F. Hoffmann-La Roche Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Merck & Co Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 GSK Plc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Johnson & Johnson
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Cipla Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Bayer AG
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 AbbVie Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 Astellas Pharma Inc
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Antibiotics and Antimycotics Market Segmentation
  • Table 2. Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Drug Class
  • Table 4. Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indication
  • Table 5. Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Route Of Administration
  • Table 6. Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 7. Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 8. Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 9. Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 10. Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 11. Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 12. France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 13. France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 14. France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 15. France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 16. Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 17. Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 18. Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 19. Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 20. Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 21. Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 22. Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 23. Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 24. United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 25. United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 26. United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 27. United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 28. Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 29. Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 30. Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 31. Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 32. Recent Organic Growth Strategies in Antibiotics and Antimycotics Market
  • Table 33. Recent Inorganic Growth Strategies in the Antibiotics and Antimycotics Market
  • Table 34. Glossary of Terms, Antibiotics and Antimycotics Market

List Of Figures

  • Figure 1. Europe Antibiotics and Antimycotics Market Segmentation - Country
  • Figure 2. Europe Antibiotics and Antimycotics Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Europe Antibiotics and Antimycotics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 6. Penicillin: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Cephalosporines: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Carbapenems: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Macrolides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Aminoglycosides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Quinolones: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 12. Sulfonamides: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Tetracyclines: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Azoles: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Europe Antibiotics and Antimycotics Market Share (%) - by Indication (2023 and 2031)
  • Figure 17. Skin Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Respiratory Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Urinary Tract Infections (UTI): Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Septicemia: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. Ear Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Gastrointestinal Infections: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 23. Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 24. Europe Antibiotics and Antimycotics Market Share (%) - by Route Of Administration (2023 and 2031)
  • Figure 25. Oral: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 26. Topical: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 27. Others: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 28. Europe Antibiotics and Antimycotics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 29. Hospital Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 30. Retail Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 31. Online Pharmacies: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 32. Europe Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 33. Germany: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 34. France: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 35. Spain: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 36. Italy: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 37. United Kingdom: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 38. Rest of Europe: Europe Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 39. Growth Strategies in Antibiotics and Antimycotics Market